Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | FUT7 | Q11130 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8810649 | 0.92 | LMNA (0.43) | LMNABLMMEN1ALDH1A1HTT | |
| SCHEMBL8811142 | 0.90 | LMNA (0.42) | LMNABLMMEN1ALDH1A1HTT | |
| SCHEMBL8814285 | 0.90 | LMNA (0.42) | LMNABLMMEN1ALDH1A1HTT | |
| SCHEMBL5635440 | 0.83 | LMNA (0.39) | LMNABLMMEN1ALDH1A1HTT | |
| SCHEMBL329793 | 0.82 | — | — | |
| SCHEMBL7256132 | 0.81 | — | — | |
| SCHEMBL8812348 | 0.80 | LMNA (0.56) | LMNABLMMEN1ALDH1A1HTT | |
| SCHEMBL17369606 | 0.80 | LMNA (0.41) | LMNABLMMEN1ALDH1A1HTT | |
| SCHEMBL8531224 | 0.79 | — | — | |
| SCHEMBL8813650 | 0.77 | TP53 (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 143 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4366733-A1 | TETRAHYDROPYRAZOLOPYRIDINE-ANALOG LIGANDS OF NLRX1 AND USES THEREOF | LANDOS BIOPHARMA, INC. (US) | 2024-05-15 | — | — | EP | disclosed |
| CN-117835980-A | Tetrahydropyrazolopyridine analog ligand of NLRX1 and application thereof | 朗多生物制药股份有限公司 | 2024-04-05 | — | — | CN | disclosed |
| EP-3927427-B1 | LANTHIONINE C-LIKE PROTEIN 2 LIGANDS, CELLS PREPARED THEREWITH, AND THERAPIES USING SAME | NIMMUNE BIOPHARMA INC (US) | 2024-02-07 | — | — | EP | disclosed |
| US-20230357210-A1 | NITROGEN-CONTAINING CONDENSED HETEROCYCLIC COMPOUND HAVING AN OXIME GROUP, AGRICULTURAL OR HORTICULTURAL HERBICIDE COMPRISING THE COMPOUND, AND METHOD FOR USING THE COMPOUND OR THE HERBICIDE | NIHON NOHYAKU CO., LTD. (JP) | 2023-11-09 | — | — | US | disclosed |
| US-20230357744-A1 | ENGINEERED TRYPTOPHAN DECARBOXYLASES AND USES THEREOF FOR SYNTHESIZING TRYPTAMINE ANALOGS | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2023-11-09 | — | — | US | disclosed |
| EP-4225315-A2 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING INFLAMMATORY OR IMMUNE-MEDIATED CONDITIONS OF SURFACE TISSUES | Nimmune Biopharma, Inc. (US) | 2023-08-16 | — | — | EP | disclosed |
| CN-116529240-A | Nitrogen-containing condensed heterocyclic compound having oxime group, agrohorticultural herbicide containing the same and method of using the same | 日本农药株式会社 | 2023-08-01 | — | — | CN | disclosed |
| EP-4214200-A1 | LANCL LIGANDS | Nimmune Biopharma, Inc. (US) | 2023-07-26 | — | — | EP | disclosed |
| CN-113748109-B | Lanthionine C-like protein 2 ligands, cells prepared with said ligands and therapies using said ligands | 朗多生物制药股份有限公司 | 2023-07-21 | — | — | CN | disclosed |
| CN-116368133-A | NLRX1 ligand | 朗多生物制药股份有限公司 | 2023-06-30 | — | — | CN | disclosed |
| EP-0536936-B1 | Pyrimidine nucleoside derivatives having anti-tumor activity, their preparation and use | SANKYO CO (JP) | 1996-08-14 | — | — | EP | disclosed |
| CN-1072686-A | Has Pyrmidine nucleoside derivatives of anti-tumor activity and its production and use | SANKYO CO (JP) | 1993-06-02 | — | — | CN | disclosed |
| EP-0537463-A2 | Substituted pyrido(2,3-d)pyrimidines as antidotes | BASF Aktiengesellschaft (DE) | 1993-04-21 | — | — | EP | disclosed |
| EP-0536936-A1 | Pyrimidine nucleoside derivatives having anti-tumor activity, their preparation and use | Sankyo Company Limited (JP) | 1993-04-14 | — | — | EP | disclosed |
| US-4281116-A | ANTIBIOTICS | ELI LILLY AND COMPANY (US) | 1981-07-28 | — | — | US | disclosed |
| US-4260745-A | 3-Halo cephalosporins | ELI LILLY AND COMPANY (US) | 1981-04-07 | — | — | US | disclosed |
| US-4252950-A | ANTIBIOTICS, BACTERICIDES, FUNGICIDES | ELI LILLY AND COMPANY (US) | 1981-02-24 | — | — | US | disclosed |
| US-4208515-A | 3-Halo cephalosporins | ELI LILLY AND COMPANY (US) | 1980-06-17 | — | — | US | disclosed |
| US-4064343-A | ANTIBIOTICS | ELI LILLY AND COMPANY (US) | 1977-12-20 | — | — | US | disclosed |
| US-3962227-A | ANTIBIOTICS | ELI LILLY AND COMPANY (US) | 1976-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357210-A1 | NITROGEN-CONTAINING CONDENSED HETEROCYCLIC COMPOUND HAVING AN OXIME GROUP, AGRICULTURAL OR HORTICULTURAL HERBICIDE COMPRISING THE COMPOUND, AND METHOD FOR USING THE COMPOUND OR THE HERBICIDE | DDT, HDHD5, HPD | LMNA 4279/4885BLM 2477/4885MEN1 2893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.